January 6, 2017

Beaten-Down Gilead Is My Top 2017 Pick


As value investors, we rarely get a chance to buy dynamic biotech companies since they typically sell at 20x (or more) earnings. In the last two decades, in those rare cases where a biotech company has sold for under 10x earnings, we have ultimately done quite well on the investment. We think Gilead Sciences (GILD) represents one of those opportunities today and feel the stock is a "table-pounding" buy.

By simple valuation metrics, the shares are dirt cheap. The company sells at 6.6x 2016's EPS of $11.40, 6.9x 2017's EPS of $10.87, and pays a 2.5% dividend. Beyond selling at a great price, the company has leading drug franchises in the HIV and hepatitis C markets and has a respectable pipeline. It also has a solid balance sheet with $4 billion of net cash, strong free cash flow at $14 billion per year and a top-tier, shareholder-oriented management team.



Source: TheStreet

No comments:

Post a Comment